Eribulin for heavily pre-treated metastatic breast cancer patients

Table 2 Eribulin treatment and results

	Median	Range
Progression-free survival (mo)	3	1-14
Overall survival (patients who died)	7	1-18
Follow-up (mo, patients alive)	13.5	7-19
Number of eribulin cycles	3	1-16
	patients (n = 21)	%
Previous lines of treatment
3 or less	8	38.1
More than 3	13	61.9
Reason for eribulin discontinuation
Progression	20	95.2
Adverse effects	1	4.8

All patients in the series had progressed at the time of data collection. Fifteen patients had died at the time of data collection and 6 patients were still alive.